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Abstract Despite recent advances in reproductive medi-
cine, there are still no effective treatments for severe
infertility caused by congenital absence of germ cells or
gonadotoxic treatments during prepubertal childhood.
However, the development of technologies for germ cell
formation from stem cells in vitro, induction of pluripo-
tency from somatic cells, and production of patient-specific
pluripotent stem cells may provide new solutions for
treating these severe fertility problems. It may be possible
to produce germ cells in vitro from our own somatic cells
that can be used to restore fertility. In addition, these
technologies may also bring about novel therapies by
helping to elucidate the mechanisms of human germ cell
development. In this review, we describe the current
approaches for obtaining germ cells from pluripotent stem
cells, and provide basic information about induction of
pluripotency and germ cell development.
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Introduction
Pluripotent stem cells have the potential to differentiate
into cells of any lineage. Embryonic stem cells (ESCs) are
pluripotent stem cells derived from the inner cell mass of
blastocysts. ESCs have been used extensively to study
mammalian development and human diseases, because
these cells can develop into all three germ layers in mouse
chimeras [1] and form teratomas [2]. Importantly, it has
also been demonstrated that ESCs can differentiate into
germ lineages (i.e., gametes) in vivo and in vitro. Detailed
investigation of the earliest stages of germ cell develop-
ment in humans is subject to practical and ethical limita-
tions. Therefore, relatively little is known about the
specification of human germ cells at primordial stages
(primordial germ cells, PGCs) [3, 4]. Thus, in vitro model
systems that can recapitulate the development of human
germ cells and gametes will be extremely valuable as
research tools.
From the first report of induced pluripotent stem cells
(iPSCs) in 2007 [5], pluripotent stem cell technologies
have grown with the goal of creating individualized,
patient-specific stem cell therapies. These technologies
may enable us to understand the causes of severe infertility
at the level of individual patients. More importantly, the
ability to produce germ cell replacements using the
patients’ own somatic cells will relieve many of the con-
straints associated with current methods for infertility
treatment.
To generate patient specific germ cell in vitro, two keys
steps are required: (1) induction of pluripotency in somatic
cells; and (2) generation of germ cells from iPSCs. In the
following sections, we describe current approaches used in
each of these steps, and discuss the possibilities and chal-
lenges for regeneration of the reproductive system.
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Induction of pluripotency: development
of ‘‘MATERIALS’’ for germ cell production
To obtain stable germ cells from iPSCs, it is important to
maintain the quality of iPSCs pluripotency. It is a well-
known fact that germ-line competency levels differ dra-
matically among ESC and iPSC lines; therefore, screening of
cell lines prior to differentiation may significantly improve
the success of germ cell induction. In mice, some predictive
markers such as Nanog [6] and Gtl2 [7] enable selection of
germline competent cells. However, it is unclear whether
these markers will be applicable to other species. Therefore,
improvements in the induction methods for creating iPSCs
may represent an additional avenue for producing germline
competent cells. To find these novel induction methods, it
will be important to elucidate the complete molecular
mechanisms for establishing pluripotency.
Pluripotency is established and maintained by a core
circuit of signaling molecules composed of Oct4, Sox2,
Nanog, and related molecules such as Klf4, Esrrb, Tbx3,
and cMyc [8, 9]. This core circuit controls expression of
pluripotency maintenance genes and is involved in epige-
netic modification. The original method for inducing plu-
ripotency is based on introduction of four reprogramming
factors: Oct4, Sox2, Klf4, and cMyc (also known as the
Yamanaka factors) [10]. Oct4, a POU homeodomain
transcription factor, is an essential factor for reprogram-
ming, and is required for pluripotency of inner cell mass
(ICM) cells and ESCs [11, 12]. Sox2 forms a complex with
Oct4 to regulate the transcription of key pluripotency
control genes, such as Oct4, Sox2, and Nanog [11, 13].
However, Sox2 is dispensable for establishment of pluri-
potency, as demonstrated by experiments where forced
expression of Oct4 rescued the undifferentiated state of
Sox2 null ESCs [11]. Furthermore, in artificial induction of
pluripotency in mouse fibroblasts, TGFb inhibitors can
replace Sox2 [14]. The Kru¨ppel-like zinc finger transcrip-
tion factor Klf4 also plays an important role in the pluri-
potency core circuit by regulating the expression of Sox2
and Nanog [8, 15]. Finally, cMyc is a major oncogene that
binds to promoters for cell-cycle activating genes and
pluripotent state-specific microRNAs (miRNAs) [16].
cMyc can also contribute to pluripotency by activating
histone acetyltransferases/demethylases, which function to
remodel chromatin, helping other pluripotency-related
transcription factors to access target genes [17]. However,
chimeras derived from cMyc-iPSCs frequently develop
tumors; therefore, replacement of cMyc with LMyc [18], or
omission of exogenous Myc, is appropriate [19] since
endogenous cMyc is already expressed at low levels in
many somatic cells. Exogenous expression of these genes
induces the following sequential reprogramming events.
First, a change resembling mesenchymal-to-epithelial
transition (MET) occurs as somatic cell-specific gene
expression is downregulated. Next, early pluripotency
markers such as alkaline phosphatase, SSEA-1, and Fbx15
become activated [20, 21]. Later on during reprogramming,
Nanog and other pluripotency-related genes become acti-
vated. Once endogenous expression of pluripotency genes
such as Nanog occurs, the cells can maintain pluripotency
independent of exogenous factors [20–22] (Fig. 1).
Oct4, Sox2, Klf4 and Myc are not the only combination
of factors that can generate iPSCs. Yu et al. reported that
Klf4 and cMyc can be replaced with Nanog, another core
member of the pluripotency maintenance circuit [23].
Lin28, a RNA binding protein, is involved in degradation
of let7 miRNAs [24, 25]. Control miRNAs capable of
inducing pluripotency are also available. Judson et al.
observed a marked increase in reprogramming upon over-
expression of the miR-290 and miR-302 clusters [26],
which are known to accelerate cell cycling [27]. Mean-
while, Anokey-Danso et al. succeeded at generating iPSCs
from both human and murine somatic cells by overex-
pression of the miR-302-367 cluster, which facilitates MET
by induction of E-cadherin expression and inhibition of
TGF-b signaling [28]. Using the same principles, Miyoshi
et al. demonstrated that iPSCs could be generated by
repetitive transient delivery of mature miRNAs from the
Fig. 1 Reprogramming of the
somatic cells by exogenous
gene expression
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miR-200c, miR-302, and miR-369 families, which are all
involved in MET [29]. On the other hand, Heng et al.
reported that the nuclear receptor Nr5a2 can replace Oct4
[30]. Recently, Maekawa et al. re-screened genes identified
from molecules enriched in unfertilized oocytes and
zygotes that enhanced induction of pluripotency, and dis-
covered a novel transcription factor, Glis1. This molecule
promotes induction with high efficiency and reduces
tumorigenicity. Interestingly, Glis1 not only interacts with
the pluripotency maintaining core-circuit molecules Oct4,
Sox2, and Klf4, but also interacts with some related pro-
teins, such as several Wnt ligands, Lin28a, Myc, and Foxa2
[31]. Better combinations of reprogramming/induction
genes may be discovered by elucidating the mechanisms of
pluripotency. Understanding the factors that regulate plu-
ripotency may help to control tumorigenicity and reveal
new methods for controlling cell differentiation.
Specification of PGCs: understanding the origin
of germ cells for development of successful induction
methods
Elucidation of the mechanisms involved in production of
‘‘native’’ germ cells will be essential for development of
technologies that generate germ cells from pluripotent stem
cells in vitro. In particular, studies pertaining to primordial
germ cells (PGCs), which give rise to oocytes and sperm,
will reveal important information that can be used for germ
cell production.
Primordial germ cells are derived from a subset of cells
in the epiblast immediately after implantation. These cells
undergo reprogramming that leads to their specification
during the few weeks that they travel through the gonadal
ridges [32, 33]. In the mouse, PGCs appear at 6.25 days
post-conception (dpc). Germ-line competence can be
identified in the first founder of Blimp1 (B-lymphocyte-
induced maturation protein 1) expressing epiblast cells [33,
34]. PGCs are readily identified at 7.25 dpc as a Stella?/
tissue nonspecific alkaline phosphatase (TNAP)? cell
population of approximately 40 cells in the developing
yolk sac. The PGCs then migrate towards the future gonads
(genital ridges) and start to express germ cell-specific
genes, such as mouse VASA homolog (MVH) [4, 35]. From
11.5 to 12.5 dpc, PGCs undergo epigenetic reprogramming,
including genome-wide demethylation, removal of parental
imprints [36], histone modifications [37], and activation of
the X chromosome [38, 39]. Finally, the PGCs enter
mitotic arrest in males or prophase of meiosis I in females
[40, 41].
In the mouse, germ cell competence of epiblast cells is
induced in response to signals from the extra-embryonic
ectoderm, including bone morphogenic proteins (BMPs)
belonging to the transforming growth factor-b (TGF-b)
superfamily. For example, when epiblasts are stimulated
with a combination of BMP4 and BMP8b, PGCs are pro-
duced [42–45]. It is assumed that BMP2 functions in PGC
specification, since inactivation of BMP2 results in fewer
PGCs [42, 43, 46].
Of course, PGC specification is also strictly controlled at
the level of gene expression. Certain genes such as Blimp1,
Stella, Fragilis, c-Kit, VASA (MVH in mouse), DAZ, and
DAZL play crucial roles in the appearance and development
of PGCs. During the first step of germ cell determination,
Fragilis-expressing cells appear and Blimp1 expression is
transiently induced [47]. Fragilis, a member of a larger
family of interferon-inducible genes, encodes a transmem-
brane protein and is the first gene to mark the onset of germ
cell induction. Fragilis may serve to increase the length of
the cell cycle in PGCs. Blimp1 is a zinc-finger containing
DNA-binding transcriptional repressor. This molecule
functions as a master regulator in the foundation of the
mouse germ cell lineage together with its partner molecule
Prdm14. Expression of Fragilis is increased in migratory
PGCs, and in turn induces expression of other germ
cell-specific genes such as Stella and VASA [48]. Stella is a
SAP-like domain and splicing factor motif-like structure-
containing protein that may function in chromatin remod-
eling or RNA processing during the development of PGCs
[49]. VASA is a widely conserved gene that encodes an
ATP-dependent RNA helicase with a DEAD-box. It is
capable of unwinding double-stranded RNA loops to pro-
mote the translation of germ line-specific genes [50, 51].
The tyrosine-kinase receptor c-Kit and its ligand, Stem Cell
Factor (SCF), are also essential for maintenance of PGCs.
SCF is expressed in Sertoli cells [52]. It is assumed that it
functions in spermatogenesis. DAZ (deleted in azoosper-
mia) is a RNA-binding protein that belongs to the DAZ
family. Men with deletions encompassing the DAZ genes
on the Y-chromosome show significant defects in germ cell
generation, indicating that they are defective in the forma-
tion and maintenance of germ cells. In humans, the DAZ
gene family encompasses genes such as BOULE, DAZ-like
(DAZL), PUM2, and DAZ encoding translational regulators
[4, 53]. DAZL is expressed throughout gametogenesis and
is involved in the translational regulation of Vasa/MVH and
synaptonemal complex protein 3 (SYCP3) in meiotic cells
[54]. Haston et al. [55] showed that disruption of DAZL in
mice affects multiple attributes of germ cell differentiation,
including failure to erase and re-establish genomic imprints
on PGCs. Loss of DAZL function in mice also decreases the
number of post-migratory, pre-meiotic PGCs and reduces
their ability to undergo normal meiosis [54].
Elucidating gene expression profiles and the functions of
master genes for germ cell specification has at least two
purposes: (1) By using our knowledge to increase the
Reprod Med Biol (2013) 12:39–46 41
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expression level of certain genes, germ cells may be
induced more effectively; and (2) By using these genes as
monitors, we can evaluate precisely the methods for germ
cell induction.
Recent advances in the germ cell differentiation
from iPS cells
Many of the foundational studies on pluripotency and dif-
ferentiation to germ cells involved ESCs. Toyooka et al.
[56] discovered that mouse ESCs (mESCs) can differentiate
into PGC-like cells that is capable of engraftment into testis
and of forming sperm. Subsequently, Hubner [57] and
Geijisen [58] demonstrated that ESC-derived germ cells can
give rise to blastocysts. In 2006, fertilization of mouse
oocytes with ESC-derived haploid cells induced in vitro
resulted in generation of live offspring, although these
expressed phenotypic abnormality and died prematurely
[59]. Appearance of PGCs and haploid cells from human
ESCs (hESCs) has also been observed [4, 60, 61]. The
above studies were based on spontaneous differentiation of
pluripotent stem cells, but germ cell differentiation is
strongly dependent on signaling molecules and the gonadal
microenvironment. Therefore, providing the correct culture
conditions is critical for inducing germ cell differentiation
from pluripotent stem cells in vitro. Co-culture systems and
conditioned medium have been used to recapitulate the
gonadal microenvironment for differentiation of germ cells.
Co-cultures containing fetal gonadal stromal cells [62],
Sertoli cells [63], or embryonic fibroblasts [64] increase the
differentiation of pluripotent stem cells to PGCs. Although
these co-culture systems may produce the desired results,
induction with chemically or biologically defined factors is
preferred, because it increases the safety of cells for clinical
applications and improves the reproducibility of the dif-
ferentiation process. Thus, supplementation of defined
media with growth factors is usually the option for inducing
differentiation. For example, BMP4 and BMP8b promote
the differentiation of ESCs into PGC-like cells [43, 44, 65],
and retinoic acid (RA) can be used to stimulate meiosis
[66]. In addition, SCF [67], leukemia inhibitory factor (LIF)
[66, 68], forskolin, GDNF (a cytokine found to support
in vitro self-renewal of spermatogonial stem cells) [69], and
adenylate cyclase activator [66] enhance germ line differ-
entiation of pluripotent stem cells. Manipulation of gene
expression can also be used to control lineage specification
of differentiating pluripotent stem cells. For example,
overexpression of DAZL and VASA promotes PGC forma-
tion from hESCs, and overexpression of DAZ and BOULE
promotes the development of haploid germ cells [70].
Recently, several reports have demonstrated production
of germ cells from iPSCs. Park et al. [62] first reported the
production of PGC-like cells by co-culture with human fetal
gonads. Panura et al. reported that BMP4 supplementation
increases differentiation to VASA-GFP-positive PGC-like
cells from hiPSCs. They went on to produce haploid cells by
overexpressing DAZ [71]. Eguizabal et al. [66] also reported
induction of haploid cells by culturing the iPSC-derived
PGCs in forskolin, LIF, bFGF and an inhibitor of CYP26 (a
P450 enzyme that catabolizes active all-trans RA into
inactive metabolites). Medrano et al. [72] improved the rate
of meiotic cell formation using plasmids to induce VASA
and DAZ overexpression in hiPSCs. Meanwhile, Saitou and
colleagues obtained fertile sperm and live mouse offspring
from iPSCs by transplanting Blimp1-Venus-positive germ
cells induced with BMP4/BMP8b/SCF/LIF and EGF-sup-
plemented medium into infertile male mice [73]. Further-
more, they recently used iPSCs to reconstruct ovary-like
tissues from Integrin-b3 ?/SSEA1 ? PGC-like cells and
fetal gonadal cells. Once transplanted into the ovarian bursa
of nude mice, these tissues generated oocytes that devel-
oped into live offspring [74].
However, despite these major advances, the conditions
for producing germ cells that can develop into normal off-
spring entirely in vitro have yet to be discovered. At present,
live offspring can only be obtained by transplanting
immature germ cells that have been partially induced
in vitro. So far, the function of these in vitro-generated germ
cells has been demonstrated only in mouse. Germ cells
develop in a species-specific manner under specific devel-
opmental periods, hormonal environments and structures of
the reproductive organs. Therefore, we will have to examine
the processes in animals that are more similar to humans.
Non-human primate models may be required. In 2007, we
demonstrated that cynomolgus monkey ESCs could differ-
entiate into PGC-like cells [75]. Yamauchi et al. [76]
improved the differentiation method by supplementing
conditioned medium from testicular or ovarian cells with
recombinant BMP4, RA, or SCF. Further studies, including
functional assays in vivo, will reveal the molecular mech-
anisms that dictate primate germ line development and
provide information that can be extrapolated to human germ
cell differentiation. Recently, Hermann et al. demonstrated
the feasibility of spermatogonial stem cell transplantation in
a nonhuman primate alkaline chemotherapy-induced
infertility model. They provided important evidence for
donor spermatogenesis in both autologous and allogeneic
transplant recipients [77]. These findings lay the ground-
work for development of future pluripotent stem cell-based
germ cell regeneration technologies.
Challenges to overcome for therapeutic utilization
of iPSCs
Although iPSCs could open a new door for reproductive
medicine, a number of significant hurdles clearly exist
42 Reprod Med Biol (2013) 12:39–46
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before these cells can be used in clinical settings. The most
important issue is whether the induced germ cells from
iPSCs are ‘‘normal’’ enough to be transplanted as a con-
ceptus. Recently, several groups reported that many iPS
cell-lines contain somatic coding mutations, copy number
variations, and aberrant epigenetic reprogramming [78–
80]. Although there is conflicting evidence, iPSCs were
found to retain epigenetic memories from their cell type of
origin that influenced lineage specification [81]. Moreover,
iPSCs from fragile X syndrome patients failed to reactivate
the fragile X mental retardation 1 (FMR1) gene [82]. These
genetic and epigenetic changes must not be carried over to
the genome of the fetus. These findings suggest that the
genetic quality of iPSCs may require more rigorous testing
before they can be applied in clinical settings. There may
be some cases where iPSC use may be inappropriate.
Another issue is the low efficiency of differentiation of
germ cells from pluripotent stem cells. As described above,
development of germ cells occurs through multiple dif-
ferentiation processes within the surrounding germinal
tissue. Therefore, step-wise differentiation protocols based
on precise levels of signaling molecules such as cytokines,
transcription factors, or cell adhesion molecules will be
required to improve the differentiation methods. To date,
an appropriate protocol for full term in vitro development
of sperm or oocytes has not been discovered. However, in
order to avoid tumorigenesis of transplanted pluripotent
stem cells, it will be necessary to develop such a process.
Thus, a comprehensive understanding of germ cell devel-
opment factors will be essential. Furthermore, some dif-
ferences are often observed in the gene expression patterns
and timing of germ cell appearance from PGCs in vivo.
Some researchers have observed haploid cell marker
expressions at only 14 days after induction [68, 70, 75]. It
is unlikely that this event reflects the precise developmental
timing of germ cells and has motivated us to improve the
systems used for differentiation.
The last issue relates to the differentiation propensity of
pluripotent stem cells [83]. Miura et al. [84] reported that
mouse iPS cell-lines produced from different tissues varied
in propensity to form teratomas. In any case, patient-spe-
cific hiPSC lines obtained from different tissues of the
same patient may produce different outcomes in terms of
germ cell differentiation rate and quality. Furthermore,
there are some cases in which germ cells cannot be pro-
duced because of mutations in the patient’s genome. For
these types of patient-specific iPSCs, Soldner et al. sug-
gested a sophisticated strategy using zinc-finger nuclease
(ZFN)-mediated genome editing. Using this technology,
they established isogenic iPSCs possessing point mutations
for genetic forms of Parkinson’s disease [85]. It is possible
that these technologies can also be applied to reverse
genetic mutations in iPSCs that are linked to severe
infertility caused by point mutations that result in abnormal
germ cell generation [86] and/or function [87], or non-
functional accessary cells [88].
Conclusion
The development of iPSCs has opened the potential to treat
many intractable diseases. These iPSC technologies will
allow us to manipulate the differentiation of patient-spe-
cific iPSCs to improve our understanding of diseases and
assist in the development of new drugs and treatments. If
the induction system enables the production of ‘‘func-
tional’’ and ‘‘completely normal’’ germ cells, it will resolve
many problems that cause infertility (Fig. 2). However, we
are currently facing several challenges for clinical use of
iPSCs, and we are just beginning to develop methods for
generating germ cells in vitro. The process of germ cell
formation is complicated. In normal gametogenesis, both
sperm development and oocyte growth and maturation
require support from Sertoli cells, theca, or granulosa cells.
Fig. 2 Pluripotent stem cell-
based germ cell generation
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Understanding the supportive niche for germ cell devel-
opment in vivo will be essential for obtaining ‘‘functional’’
germ cells at more advanced stages in vitro. Although
many challenges remain, the generation of gametes using
these approaches may improve the future of reproductive
biology and medicine.
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